Document Detail

Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.
MedLine Citation:
PMID:  24398888     Owner:  NLM     Status:  Publisher    
BACKGROUND: The purpose of this study was to determine among maintenance hemodialysis patients with echocardiographic left ventricular hypertrophy and hypertension whether in comparison with a β-blocker-based antihypertensive therapy, an angiotensin converting enzyme-inhibitor-based antihypertensive therapy causes a greater regression of left ventricular hypertrophy.
METHODS: Subjects were randomly assigned to either open-label lisinopril (n = 100) or atenolol (n = 100) each administered three times per week after dialysis. Monthly monitored home blood pressure (BP) was controlled to <140/90 mmHg with medications, dry weight adjustment and sodium restriction. The primary outcome was the change in left ventricular mass index (LVMI) from baseline to 12 months.
RESULTS: At baseline, 44-h ambulatory BP was similar in the atenolol (151.5/87.1 mmHg) and lisinopril groups, and improved similarly over time in both groups. However, monthly measured home BP was consistently higher in the lisinopril group despite the need for both a greater number of antihypertensive agents and a greater reduction in dry weight. An independent data safety monitoring board recommended termination because of cardiovascular safety. Serious cardiovascular events in the atenolol group occurred in 16 subjects, who had 20 events, and in the lisinopril group in 28 subjects, who had 43 events {incidence rate ratio (IRR) 2.36 [95% confidence interval (95% CI) 1.36-4.23, P = 0.001]}. Combined serious adverse events of myocardial infarction, stroke and hospitalization for heart failure or cardiovascular death in the atenolol group occurred in 10 subjects, who had 11 events and in the lisinopril group in 17 subjects, who had 23 events (IRR 2.29, P = 0.021). Hospitalizations for heart failure were worse in the lisinopril group (IRR 3.13, P = 0.021). All-cause hospitalizations were higher in the lisinopril group [IRR 1.61 (95% CI 1.18-2.19, P = 0.002)]. LVMI improved with time; no difference between drugs was noted.
CONCLUSIONS: Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; number: NCT00582114).
Rajiv Agarwal; Arjun D Sinha; Maria K Pappas; Terri N Abraham; Getachew G Tegegne
Related Documents :
10234728 - Intermittent p wave sensing in a patient with ddd pacemaker.
7273038 - Sudden disappearance and reappearance of the pathologic q waves after successive myocar...
8112918 - Increase of r-wave in pre-discharge ergometric test after myocardial infarction indicat...
25130788 - Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for ac...
6657538 - Severe left ventricular dysfunction in critical aortic stenosis--reversal following aor...
18467888 - Urgent invasive coronary strategy in patients with sudden cardiac arrest.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-1-6
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  -     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-1-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lateralizing Epidural Catheter Placement as Evidenced by Electrical Stimulation.
Next Document:  Homoarginine, kidney function and cardiovascular mortality risk.